Cancer Drug Deal Carries High Price -- WSJ
2019年3月30日 - 4:02PM
Dow Jones News
By Denise Roland and Carlo Martuscelli
This article is being republished as part of our daily
reproduction of WSJ.com articles that also appeared in the U.S.
print edition of The Wall Street Journal (March 30, 2019).
AstraZeneca PLC has agreed to pay Japan's Daiichi-Sankyo Co. up
to $6.9 billion for shared rights to a new cancer drug, as the
British drugmaker expands further in the oncology market.
The Japanese drugmaker, which will retain exclusive rights to
the treatment in its home country, will get $1.35 billion upfront,
with further payments dependent on the drug's development and sales
performance. In return, AstraZeneca said it will receive half the
profit from future sales outside Japan.
The drug, DS-8201, targets a range of cancers, including breast,
gastric and lung, that produce a protein known as HER2. The
treatment, which combines a near-replica of Roche Holding AG's
Herceptin breast-cancer drug with another drug, has shown promise
in testing on certain difficult-to-treat cancers.
The therapy is designed to leave healthy tissue alone -- in
contrast with traditional chemotherapy that cannot differentiate
between tumor and normal cells.
Daiichi-Sankyo plans to start submitting DS-8201 for regulatory
review later this year. Analysts say they expect the drug to notch
annual sales of more than $3 billion at its peak.
AstraZeneca has been betting big on cancer treatments as part of
its efforts to return to growth after a string of patent
expirations. The Cambridge, England-based company last year
recorded its strongest sales growth in a decade as those efforts
started to pay off.
However, developing new cancer drugs is an increasingly
competitive area as the world's biggest pharmaceuticals companies
seek to commercialize scientific advances. Rivals such as Pfizer
Inc. and GlaxoSmithKline PLC are also focusing more on
oncology.
To help fund its deal with Daiichi-Sankyo, AstraZeneca said it
would raise $3.5 billion by selling new shares. More than half of
that sum will go toward the deal and the continuing collaboration
with the Japanese drugmaker. AstraZeneca expects its rights to
DS-8201 to boost core earnings from 2020.
Chief Financial Officer Marc Dunoyer said the company decided to
raise equity to preserve its investment-grade credit rating.
AstraZeneca shares fell 5.6% on Friday.
Jefferies analyst Peter Welford said the deal made strategic
sense but represented a significant financial outlay.
The deal is the first big move under José Baselga, a prominent
cancer doctor who now leads AstraZeneca's oncology research and
development. Dr. Baselga, who joined the company at the start of
the year, was among the doctors who ran clinical trials for
DS-8201.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
March 30, 2019 02:47 ET (06:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
過去 株価チャート
から 5 2024 まで 6 2024
Daiichi Sankyo (PK) (USOTC:DSNKY)
過去 株価チャート
から 6 2023 まで 6 2024